Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 11
Submit an article Journal homepage
284
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after ‘Day 14’ without further therapy in acute myeloid leukemia

Xueyan ChenDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA; Correspondence[email protected]
,
Megan OthusDepartment of Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
,
Brent L. WoodDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA;
,
Roland B. WalterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ;Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA; ;Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
,
Mary-Elizabeth M. PercivalClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ;Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA;
,
Pamela S. BeckerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ;Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA; ;Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
,
Paul C. HendrieDivision of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA;
,
Frederick R. AppelbaumClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ;Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
&
Elihu H. EsteyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ;Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA; ;Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
 show all
Pages 2717-2719 | Received 09 Dec 2016, Accepted 26 Feb 2017, Published online: 28 Mar 2017

References

  • O’Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 2. 2013. J Natl Compr Canc Netw. 2013;11:1047–1055.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JCO. 2003;21:4642–4649.
  • Yezefski T, Xie H, Walter R, et al. Value of routine ‘day 14’ marrow exam in newly diagnosed AML. Leukemia. 2015;29:247–249.
  • Yanada M, Borthakur G, Ravandi F, et al. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica. 2008;93:1263–1265.
  • Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol. 2009;131:16–26.
  • Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. JCO. 2012;30:3625–3632.
  • Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood. 2012;120:1581–1588.
  • Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JCO. 2011;29:1190–1197.
  • Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006;130:680–690.
  • Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol. 2013;999:123–136.
  • Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083.
  • Nachman J, Sather HN, Gaynon PS, et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children’s Cancer Group. JCO. 1997;15:2222–2230.
  • Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. JCO. 2013;31:3889–3897.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.